ENTA broke $51 this morning. It had dropped to just under $39 in mid June. This rebound could be a delayed response to the the law suit for patent infringement against PFE, anticipation of the phase I safety data for their Covid-19 protease inhibitor EDP-235, a general rebound after a long decline or all three. We should soon know about the phase I data.